These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 16943856)
1. Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Kumar M; Hunag Y; Glinka Y; Prud'homme GJ; Wang Q Gene Ther; 2007 Jan; 14(2):162-72. PubMed ID: 16943856 [TBL] [Abstract][Full Text] [Related]
2. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Soltani N; Kumar M; Glinka Y; Prud'homme GJ; Wang Q Gene Ther; 2007 Jun; 14(12):981-8. PubMed ID: 17410180 [TBL] [Abstract][Full Text] [Related]
3. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice. Chung HS; Oh JY; Yoo SB; Lee SM; Cho HS Regul Pept; 2011 Oct; 170(1-3):1-3. PubMed ID: 21621561 [TBL] [Abstract][Full Text] [Related]
4. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721 [TBL] [Abstract][Full Text] [Related]
7. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Lee YS; Shin S; Shigihara T; Hahm E; Liu MJ; Han J; Yoon JW; Jun HS Diabetes; 2007 Jun; 56(6):1671-9. PubMed ID: 17369525 [TBL] [Abstract][Full Text] [Related]
9. A site-specific genomic integration strategy for sustained expression of glucagon-like peptide-1 in mouse muscle for controlling energy homeostasis. Liu R; Li Y; Hu R; Jin T; Deng S; Liang W; Zhang N; Chen J; Prud'homme GJ; Jia WW; Ma D; Wang Q Biochem Biophys Res Commun; 2010 Dec; 403(2):172-7. PubMed ID: 21070745 [TBL] [Abstract][Full Text] [Related]
10. Biological activity of AC3174, a peptide analog of exendin-4. Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977 [TBL] [Abstract][Full Text] [Related]
11. Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcγRIIb. Liang Y; Qiu H; Glinka Y; Lazarus AH; Ni H; Prud'homme GJ; Wang Q J Gene Med; 2011 Sep; 13(9):470-7. PubMed ID: 21786368 [TBL] [Abstract][Full Text] [Related]
12. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice. Youn YS; Jeon JE; Chae SY; Lee S; Lee KC Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839 [TBL] [Abstract][Full Text] [Related]
13. Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector. Choi SH; Lee HC Gene Ther; 2011 Feb; 18(2):155-63. PubMed ID: 20720576 [TBL] [Abstract][Full Text] [Related]
14. GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment. Gan Y; Dang N; Qu Z; Shi R; Ding L; Wang L; Pang S Exp Clin Endocrinol Diabetes; 2015 Jun; 123(6):371-5. PubMed ID: 25962403 [TBL] [Abstract][Full Text] [Related]
15. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308 [TBL] [Abstract][Full Text] [Related]
16. Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc. Yang Y; Chen F; Wan D; Liu Y; Yang L; Feng H; Cui X; Gao X; Song H PLoS One; 2016; 11(5):e0156449. PubMed ID: 27232339 [TBL] [Abstract][Full Text] [Related]
17. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Prud'homme GJ; Chang Y Gene Ther; 1999 May; 6(5):771-7. PubMed ID: 10505100 [TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. Huang YS; Chen Z; Chen YQ; Ma GC; Shan JF; Liu W; Zhou LF J Pept Sci; 2008 May; 14(5):588-95. PubMed ID: 17994612 [TBL] [Abstract][Full Text] [Related]
19. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Jean M; Alameh M; Buschmann MD; Merzouki A Gene Ther; 2011 Aug; 18(8):807-16. PubMed ID: 21412280 [TBL] [Abstract][Full Text] [Related]
20. The potential role of glucagon-like peptide 1 in diabetes. Meier JJ; Nauck MA Curr Opin Investig Drugs; 2004 Apr; 5(4):402-10. PubMed ID: 15134281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]